West Lori J
Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Jun;5(3):223-32. doi: 10.2174/1568006054064762.
In order for ABO-incompatible organ transplantation to be performed successfully, the antibody response must be targeted. Aggressive strategies are usually required both to remove pre-existing antibodies directed at donor A/B antigens and to suppress further production of antibodies. If this can be accomplished in the short-term, graft accommodation of ABO-incompatible transplants may develop upon eventual re-accumulation of antibodies as the graft acquires resistance to antibody-mediated damage. In contrast to mature individuals, very young infants lack isohemagglutinins due to a natural lag in development of immunity to T cell-independent polysaccharide antigens. This delay in maturation permits a window of safety during which infants can receive ABO-incompatible grafts without the requirement for aggressive immunosuppressive strategies. We have recently demonstrated that ABO-incompatible heart transplantation performed during this stage of immaturity is followed by the spontaneous development of donor-specific B cell tolerance rather than graft accommodation, and that tolerance in this setting occurs by a cellular mechanism of antigen-specific B cell elimination. This finding is strikingly similar to the original descriptions of neonatal T cell tolerance in mice. Our data provide compelling justification that every effort should be made to include juvenile recipients routinely as subjects in tolerance research. Through understanding the mechanisms underlying tolerance in this setting, as with murine models of neonatal tolerance originally described by Medawar and colleagues, it may be possible to expand the potential applications of tolerance strategies to older patient populations.
为使ABO血型不相容的器官移植成功进行,必须针对抗体反应。通常需要采取积极策略,既要清除针对供体A/B抗原的预先存在的抗体,又要抑制抗体的进一步产生。如果能在短期内实现这一点,随着移植物获得对抗体介导损伤的抗性,当抗体最终重新积累时,ABO血型不相容移植的移植物适应性可能会发展。与成熟个体不同,非常年幼的婴儿由于对T细胞非依赖性多糖抗原的免疫发育自然滞后而缺乏同种血凝素。这种成熟延迟允许一个安全窗口,在此期间婴儿可以接受ABO血型不相容的移植物,而无需积极的免疫抑制策略。我们最近证明,在这种未成熟阶段进行的ABO血型不相容心脏移植后,会自发产生供体特异性B细胞耐受性而非移植物适应性,并且在这种情况下的耐受性是通过抗原特异性B细胞消除的细胞机制发生的。这一发现与小鼠新生儿T细胞耐受性的最初描述惊人地相似。我们的数据提供了令人信服的理由,即应尽一切努力将幼年受者作为受试者常规纳入耐受性研究。通过了解这种情况下耐受性的潜在机制,就像最初由梅达沃及其同事描述的小鼠新生儿耐受性模型一样,有可能将耐受性策略的潜在应用扩展到年龄较大的患者群体。